Marketing-authorisation holder · Germany
Fresenius Kabi Deutschland Gmbh
111 medicines in 5 countries, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder · Germany
111 medicines in 5 countries, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 111
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AMINOVEN 10% SOLUCION PARA PERFUSION5,1 g + 2,2 g + 11 g + 30 g + 5 g + 7,4 g + 4,4 g + 4,3 g + 11,2 g + 9,31 g + 6,2 g + 14 g + 0,4 g + 12 g + 1 g + 6,5 g · Solución para perfusión | Phenylalanine, Tryptophan, Glycine, Histidine, Isoleucine, Amino acids, Threonine, Methionine, Proline, Lysine, Valine, Alanine, Tyrosine, Arginine, Taurine, Serine | Spain | Marketed | 2000 |
| AMINOVEN 15% SOLUCION PARA PERFUSION5,5 g + 1,6 g + 18,5 g + 7,3 g + 5,2 g + 8,9 g + 8,6 g + 3,8 g + 17 g + 15,66 g + 5,5 g + 25 g + 0,4 g + 20 g + 2 g + 9,6 g · Solución para perfusión | Phenylalanine, Tryptophan, Glycine, Histidine, Isoleucine, Amino acids, Threonine, Methionine, Proline, Lysine, Valine, Alanine, Tyrosine, Arginine, Taurine, Serine | Spain | Marketed | 2000 |
| AZACITIDINA KABIPolvere per sospensione iniettabile | Azacitidine | Italy | Authorised | |
| AZACITIDINA KABI 25 MG/ML POLVO PARA SUSPENSION INYECTABLE EFG100 mg · Polvo para suspensión inyectable | Azacitidine | Spain | Authorised | 2024 |
| Azacitidine Kabi | Azacitidine | EU (EMA) | Authorised | 2024 |
| Azacitidine Kabi 25 mg/ml poeder voor suspensie voor injectiePoeder voor suspensie voor injectie | Azacitidine | Netherlands | Authorised | 2024 |
| Bomyntra | Denosumab | EU (EMA) | Authorised | 2025 |
| BOMYNTRASoluzione iniettabile | Denosumab | Italy | Authorised | |
| Bomyntra 120 mg oplossing voor injectie in injectieflaconOplossing voor injectie | Denosumab | Netherlands | Authorised | 2025 |
| Bomyntra 120 mg oplossing voor injectie in voorgevulde spuitOplossing voor injectie | Denosumab | Netherlands | Authorised | 2025 |
| BOMYNTRA 120 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA70 mg/ml · Solución inyectable | Denosumab | Spain | Marketed | 2025 |
| BOMYNTRA 120 MG SOLUCION INYECTABLE EN VIAL70 mg/ml · Solución inyectable | Denosumab | Spain | Marketed | 2025 |
| BORTEZOMIB FRESENIUS KABIPolvere per soluzione iniettabile | Bortezomib | Italy | Authorised | |
| Bortezomib Fresenius Kabi | Bortezomib | EU (EMA) | Authorised | 2019 |
| BORTEZOMIB FRESENIUS KABI 1 mg POLVO PARA SOLUCION INYECTABLE EFG1 mg · Polvo para solución inyectable | Bortezomib | Spain | Authorised | 2021 |
| BORTEZOMIB FRESENIUS KABI 2,5 mg POLVO PARA SOLUCION INYECTABLE EFG2,5 mg · Polvo para solución inyectable | Bortezomib | Spain | Authorised | 2021 |
| Bortezomib Fresenius Kabi 3,5 mg poeder voor oplossing voor injectie.Poeder voor oplossing voor injectie | Bortezomib | Netherlands | Authorised | 2019 |
| BORTEZOMIB FRESENIUS KABI 3,5 MG POLVO PARA SOLUCION INYECTABLE EFG3,5 mg · Polvo para solución inyectable | Bortezomib | Spain | Marketed | 2021 |
| BUSULFAN FRESENIUS KABIConcentrato per soluzione per infusione | Busulfan | Italy | Authorised | |
| Busulfan Fresenius Kabi | Busulfan | EU (EMA) | Authorised | 2014 |
| Busulfan Fresenius Kabi 6 mg/ml, concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie | Busulfan | Netherlands | Authorised | 2014 |
| BUSULFANO FRESENIUS KABI 6 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFG60 mg · Concentrado para solución para perfusión | Busulfan | Spain | Marketed | 2014 |
| Conexxence | Denosumab | EU (EMA) | Authorised | 2025 |
| CONEXXENCESoluzione iniettabile in siringa pre-riempita | Denosumab | Italy | Authorised | |
| Conexxence 60 mg oplossing voor injectie in een voorgevulde spuitOplossing voor injectie | Denosumab | Netherlands | Authorised | 2025 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 43 | 37 | 6 | CompaniesAll medicines |
| Netherlands | 22 | 22 | 0 | CompaniesAll medicines |
| Romania | 19 | 0 | 19 | CompaniesAll medicines |
| Italy | 14 | 14 | 0 | CompaniesAll medicines |
| European Union (EMA) | 13 | 12 | 1 | CompaniesAll medicines |
Also in the registers of Brazil, Croatia, France, Serbia, Singapore, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.